2-(2,6-dichloro-4-nitrophenyl)acetonitrile | 88135-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,6-dichloro-4-nitrophenyl)acetonitrile
• 英文别名: 2,6-Dichloro-4-nitrobenzeneacetonitrile
• CAS: 88135-30-2
• 化学式: C₈H₄Cl₂N₂O₂
• 分子量: 231.038
• InChiKey: VHRGXLUIOTZSQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2,6-dichloro-4-nitrophenyl)acetonitrile 在 盐酸 、 硫酸 、 1,3-双(二苯基膦)丙烷 、 potassium tert-butylate 、 palladium diacetate 、 溶剂黄146 、 三乙胺 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙腈 为溶剂， 20.0~120.0 ℃ 、310.27 kPa 条件下， 反应 28.5h， 生成 3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-ylmethyl)benzoic acid methyl ester
  参考文献：
  名称：

  Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

  摘要：

  The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor beta (THR-beta) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor alpha (THR-alpha). A pyridazinone series has been identified that is significantly more THR-beta selective than earlier analogues. Optimization of this series by the addition of a cyanoazauracil substituent improved both the potency and selectivity and led to MGL-3196 (53), which is 28-fold selective for THR-beta over THR-alpha in a functional assay. Compound 53 showed outstanding safety in a rat heart model and was efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. In reported studies in healthy volunteers, 53 exhibited an excellent safety profile and decreased LDL cholesterol (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.

  DOI：

  10.1021/jm4019299
• 作为产物：
  描述：

  1,2,3-三氯-5-硝基苯 在 sodium hydride 、 lithium chloride 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 17.5h， 生成 2-(2,6-dichloro-4-nitrophenyl)acetonitrile
  参考文献：
  名称：

  THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

  摘要：

  本文提供了化合物，优选为甲状腺激素受体β（THR beta）激动剂化合物，其组成物，以及它们的制备方法，激动THR beta的方法以及治疗由THR beta介导的疾病的方法。

  公开号：

  US20200062742A1

文献信息

• THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
  申请人：Terns, Inc.

  公开号：US20200115362A1

  公开（公告）日：2020-04-16

  Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

  本文提供了化合物，优选为甲状腺激素受体β（THR beta）激动剂化合物，其组成，其制备方法，激动THR beta的方法以及治疗由THR beta介导的疾病的方法。
• [EN] CYCLOPROPYL DERIVATIVES AS ROR-GAMMA MODULATORS<br/>[FR] DÉRIVÉS DE CYCLOPROPYLE EN TANT QUE MODULATEURS DE ROR-GAMMA
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2018011746A1

  公开（公告）日：2018-01-18

  The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them (Formula I).

  本发明提供了调节RORγ的化合物，以及它们用于治疗由RORγ介导的疾病或症状。此外，本发明涉及制备这些化合物的过程，它们的互变异构体形式，参与合成的新中间体，它们的药用盐，使用这些化合物的方法以及含有它们的药物组合物（公式I）。
• [EN] NOVEL COMPOUNDS AS ROR-GAMMA MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS EN TANT QUE MODULATEURS DE ROR-GAMMA
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2018193297A1

  公开（公告）日：2018-10-25

  The present invention provides compounds which are modulators of RORϒ and their use for the treatment of diseases or conditions mediated by RORϒ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, deuterated form, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them. formula (I)

  本发明提供了调节RORϒ的化合物，以及它们用于治疗由RORϒ介导的疾病或症状。此外，本发明涉及制备这些化合物的过程，它们的互变异构体、氘代形式、合成过程中涉及的新型中间体、药用盐、使用这些化合物的方法以及含有它们的药物组合物。公式（I）
• [EN] POLYCYCLIC COMPOUNDS AS ROR-GAMMA MODULATORS<br/>[FR] COMPOSÉS POLYCYCLIQUES EN TANT QUE MODULATEURS DE ROR-GAMMA
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2018011747A1

  公开（公告）日：2018-01-18

  The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.

  本发明提供了调节RORγ的化合物，以及它们用于治疗由RORγ介导的疾病或症状。此外，本发明涉及制备这些化合物的过程，它们的互变异构体形式，参与其合成的新型中间体，它们的药用盐，使用这些化合物的方法以及含有它们的药物组合物。
• NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE
  申请人：Bonnet Beatrice

  公开号：US20100249123A1

  公开（公告）日：2010-09-30

  The present invention provides new compounds of formula I, wherein Q, R 1 , R 2 , R 4 , R 5 , R 6 , X i , R 7 , R 8 , M and G 1 n are defined as in formula I; invention compounds are modulators of follicle-stimulating hormone—(“FSH”) which are useful for male and female contraception as well as other disorders modulated by FSH receptor.

  本发明提供了新的I式化合物，其中Q、R1、R2、R4、R5、R6、Xi、R7、R8、M和G1n如I式中所定义；发明化合物是促卵泡素-（“FSH”）的调节剂，可用于男性和女性避孕以及其他受FSH受体调节的疾病。